Scholar Rock Holding Corp (SRRK) — Technical state
As of 2026-11-10 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.
The Closelooknet read
- Closelooknet score: 27 out of 100 (momentum 58 · quality 1), as of 2026-11-11.
- Signal: Recovery attempt under the 200-day — Trades +2.5% vs the 50-day and -0.5% vs the 200-day average, 22.3% below the 52-week high and +66.7% off the 52-week low; a death cross printed 6 sessions ago. Computed from daily closes. (as of 2026-11-10)
- Trend: Scholar Rock Holding Corp trades 2.5% above its 50-day and 0.5% below its 200-day moving average. (as of 2026-11-10)
Scholar Rock develops antibody drugs that target the latent, or inactive, forms of growth factors in the TGF-beta family, aiming to treat rare neuromuscular diseases. Its lead candidate, apitegromab, blocks myostatin activation and is in mid-stage trials for spinal muscular atrophy and facioscapulohumeral muscular dystrophy.
The full read — the desk's view, the earnings record, peers and the company snapshot — is on the SRRK overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.
Trades +2.5% vs the 50-day and -0.5% vs the 200-day average, 22.3% below the 52-week high and +66.7% off the 52-week low; a death cross printed 6 sessions ago. Computed from daily closes.
The moving-average stack
- vs 20-day+10.5%
- vs 50-day+2.5%
- vs 200-day-0.5%
- 52-week band22.3% off the high · +66.7% off the low
- Streak1 consecutive down session
- CrossoverDeath cross 6 sessions ago
- 50-day crossprice crossed up through the 50-day 1 sessions ago
- Stochastic%K 64.2 · %D 90.5 · bear cross
Continue: the SRRK chart & overview · quality & forensics · the earnings record · the signal board
FAQ · from the current data · as of 2026-11-10
Quick answers
What is the current Closelooknet signal on SRRK?
Recovery attempt under the 200-day — Trades +2.5% vs the 50-day and -0.5% vs the 200-day average, 22.3% below the 52-week high and +66.7% off the 52-week low; a death cross printed 6 sessions ago. Computed from daily closes. As of 2026-11-10; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.
Is SRRK above its 50-day and 200-day moving averages?
As of 2026-11-10, Scholar Rock Holding Corp trades +2.5% above its 50-day and -0.5% below its 200-day average, with the 20-day +10.5% away.
How far is SRRK from its 52-week high?
22.3% below the 52-week high and 66.7% above the 52-week low, as of 2026-11-10.
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- HALO Halozyme Therapeutics Incindustry
- ARGX.BR Argen-Xindustry
- ONC BeOne Medicines AGindustry
- REGN Regeneron Pharmaceuticals Incindustry
- UCB.BR UCB SAindustry
- ARGX argenx NV ADRindustry
- REPL Replimune Group Incindustry
- KOD Kodiak Sciences Incindustry
- XNCR Xencor Incindustry
- VCEL Vericel Corp Ordindustry
- VRDN Viridian Therapeutics Incindustry
- SEPN Septerna, Inc. Common Stockindustry
- MRNA Moderna Incindustry
- MAZE Maze Therapeutics, Inc. Common Stockindustry
- ORKA Oruka Therapeutics, Inc.industry
- ADMA ADMA Biologics Incindustry
- PHARM.AS Pharming Group NVindustry
- MEDCL.PA Medincell SAindustry
- DNA Ginkgo Bioworks Holdingsindustry
- NEU.AU Neuren Pharmaceuticals Ltdindustry